98%
921
2 minutes
20
BackgroundMethods for measuring activated clotting time (ACT) are not yet standardized.ObjectivesTo adjust and compare values between two measurement systems and to optimize ACT during atrial fibrillation (AF) ablation.MethodsTwo systems were compared: electromagnetic detection using a rotating tube (EM system; Hemochron Response) and photo-optical detection using a cartridge immersed in blood (PO system; ACT CA-300TM).ResultsACT was measured simultaneously in 124 instances in 53 patients before and during AF ablations using both methods. A linear regression analysis showed ACT (EM system) = 1.19 × ACT (PO system) + 9.03 (p < .001, r = 0.90). Bland-Altman plots indicated an average difference of 50 s between the two systems. In 3364 ACT measurements from 1161 ablations, the EM system recorded a mean ACT of 320 ± 44 s (range 156-487 s). Estimating the target range as mean ± 1 SD range, the EM system's range was 275-365 s, in 5-s increments. The pre-ablation ACT measured on the EM system was 143 ± 28 s (115-170 s). Cardiac tamponade occurred in 4 out of 2085 ablations (0.19%) over 5 years, with ACT values ranging from 330 to 391 s on the EM system. Based on these findings, the estimated optimal ACT range for the PO system was adjusted to 225-300 s to align with the EM system's range of 275-365 s.ConclusionsACT target ranges should be system-specific, and direct extrapolation between devices is not recommended. Adjustment is clinically necessary when switching systems.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954560 | PMC |
http://dx.doi.org/10.1177/10760296251332938 | DOI Listing |
Curr Gene Ther
September 2025
Centre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
Gene therapy has revolutionized the therapeutic landscape for hemophilia A and B, offering the prospect for persistent endogenous production of coagulation factors VIII and IX. Recent advances in adeno-associated virus (AAV)-mediated gene transfer, particularly the approvals of valoctocogene roxaparvovec (Roctavian) and etranacogene dezaparvovec (Hemgenix), mark significant milestones in hemophilia care. This mini-review synthesizes emerging clinical data from phase I-III trials published between 2022 and 2025, emphasizing efficacy, durability, and immunogenicity profiles of leading AAV-based therapies.
View Article and Find Full Text PDFThromb Res
September 2025
Department of Hematology, Radboud university medical centre, Nijmegen, the Netherlands; Hemophilia Treatment Centre Nijmegen-Eindhoven-Maastricht, Nijmegen, the Netherlands. Electronic address:
Introduction: Very rare bleeding disorders (VRBDs) are hereditary disorders which cause increased risk of bleeding. In general, VRBDs consists of rare platelet function disorders, very rare coagulation factor deficiencies (other than Factor (F) VIII or FIX) and disorders of the fibrinolytic pathway. The rarity of these disorders along with the scarcity of specialized hemostasis laboratories capable to perform the necessary diagnostic tests, results in significant challenges in diagnosing and monitoring patients with VRBD.
View Article and Find Full Text PDFUrol J
September 2025
Affiliated Hospital of Nantong University, Emergency Department, Nantong, 226000, Jiangsu, China.
Purpose: Urosepsis, a condition caused by a urinary tract infection spreading to the bloodstream, has a complex epigenetic behavior in its cellular and molecular pathophysiology. The objective of this study was to identify relevant genes and signaling pathways in adult urosepsis through a bioinformatic analysis of differentially expressed genes (DEGs).
Materials And Methods: In this in-silico study, the GSE69528 dataset, containing 138 total RNA blood samples from patients with sepsis and uninfected controls, was obtained from the Gene Expression Omnibus (GEO) database.
Transfusion
September 2025
Research and Development, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Background: Cold-stored platelets (CSP) are now being used to treat acute bleeding. However, as CSP are less suitable for prophylaxis, both room temperature (RT) platelets and CSP will be required, which complicates inventory management. The production of CSP "on-demand" from RT platelets may be a desirable option.
View Article and Find Full Text PDFPharmacotherapy
September 2025
Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan, USA.
Introduction: Pediatric plastic bronchitis (PB) is a rare complication of surgically palliated congenital heart disease (CHD). Fibrin casts obstruct airways and can cause respiratory distress. There are no therapeutics approved by the United States Food and Drug Administration to treat PB, but inhaled tissue plasminogen activator (tPA) has been anecdotally used to relieve symptoms.
View Article and Find Full Text PDF